J 2016

Clinical Potential of Effective Noninvasive Exclusion of KEL1-Positive Fetuses in KEL1-Negative Pregnant Women

BÖHMOVA, Jana; Radek VODICKA; Marek LUBUSKY; Iva HOLUSKOVA; Martina STUDNICKOVA et al.

Základní údaje

Originální název

Clinical Potential of Effective Noninvasive Exclusion of KEL1-Positive Fetuses in KEL1-Negative Pregnant Women

Autoři

BÖHMOVA, Jana; Radek VODICKA; Marek LUBUSKY; Iva HOLUSKOVA; Martina STUDNICKOVA; Romana KRATOCHVILOVA; Eva KREJCIRIKOVA; Maria JANIKOVA; Veronika DURDOVÁ; Tereza DOLEZALOVÁ; Hana FILIPOVÁ; Ladislav DUŠEK; Ishraq DHAIFALAH; Katherine VOMACKOVA; Marian KACEROVSKY; Martin PROCHAZKA a Radek VRTEL

Vydání

Fetal Diagnosis and Therapy, Basel, Karger, 2016, 1015-3837

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.699

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00090556

Organizační jednotka

Lékařská fakulta

UT WoS

000380144600007

EID Scopus

2-s2.0-84945152345

Klíčová slova anglicky

Noninvasive fetal genotyping; KEL1; Minisequencing; Kell blood group system; Red blood cell alloimmunization; Hemolytic disease of the fetus and newborn

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 25. 8. 2016 08:52, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background: The clinical importance of assessing the fetal KEL genotype is to exclude 'K'-positive fetuses (genotype KEL1/KEL2) in 'K'-alloimmunized pregnant women (genotype KEL2/KEL2). Noninvasive assessment of the fetal KEL genotype is not yet available in the Czech Republic. Objective: The aim of this study was to assess the fetal KEL1/KEL2 genotype from cell-free fetal DNA in the plasma of KEL2/KEL2 pregnant women. Methods: The fetal genotype was assessed by minisequencing (a dilution series including control samples). A total of 138 pregnant women (between the 8th and 23rd gestational week) were tested by minisequencing. The fetal genotype was further verified by analysis of a buccal swab from the newborn. Results: Minisequencing proved to be a reliable method. In 2.2% (3/138) of the examined women, plasma sample testing failed; 94.8% (128/135) had the KEL2/KEL2 genotype, and a total of 3.1% of fetuses (4/128) had the KEL1/KEL2 genotype. Sensitivity and specificity reached 100% (p < 0.0001). Conclusion: Minisequencing is a reliable method for the assessment of the fetal KEL1 allele from the plasma of KEL2/KEL2 pregnant women.